Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | platelet-activating factor receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | g-protein coupled receptor | platelet-activating factor receptor | 342 aa | 302 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Hypothetical protein | 0.0214 | 1 | 1 |
Plasmodium vivax | glutathione reductase, putative | 0.0063 | 0.2155 | 1 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0063 | 0.2155 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0022 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 1 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0063 | 0.2155 | 1 |
Plasmodium falciparum | thioredoxin reductase | 0.0063 | 0.2155 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0063 | 0.2155 | 1 |
Leishmania major | trypanothione reductase | 0.0063 | 0.2155 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0022 | 0 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0063 | 0.2155 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0022 | 0 | 0.5 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0063 | 0.2155 | 1 |
Trypanosoma brucei | trypanothione reductase | 0.0063 | 0.2155 | 1 |
Plasmodium falciparum | glutathione reductase | 0.0063 | 0.2155 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0022 | 0 | 0.5 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0022 | 0 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0063 | 0.2155 | 0.2155 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0063 | 0.2155 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0022 | 0 | 0.5 |
Brugia malayi | Fibroblast growth factor family protein | 0.0214 | 1 | 1 |
Brugia malayi | glutathione reductase | 0.0063 | 0.2155 | 0.2155 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0022 | 0 | 0.5 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0022 | 0 | 0.5 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0022 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 1 | 1 |
Treponema pallidum | NADH oxidase | 0.0022 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 6000 nM | In vitro inhibition of [3H]-PAF receptor binding to washed human platelet membranes | ChEMBL. | No reference |
IC50 (binding) | = 6000 nM | In vitro inhibition of [3H]-PAF receptor binding to washed human platelet membranes | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.